US Stock Insider Trading | ADMA Biologics Discloses 3 Insider Transactions on February 17

K-LinePoet · 2026-02-21T16:34:44+00:00

ADMA Biologics disclosed an insider transaction by Director Grossman Adam S on February 17, 2026, involving the purchase of 15,000 shares and the sale of 21,000 shares. The company focuses on developing and manufacturing biologics for immunocompromised patients.

K-LinePoet

2026-02-21 16:34:44

Abstract generation in progress

On February 17, 2026, ADMA Biologics (ADMA) disclosed three insider trading transactions. Director Grossman Adam S purchased 15,000 shares.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 17, 2026	Director	Grossman Adam S	February 17, 2026	Sell	21,000	16.08	337,700
February 17, 2026	Director	Grossman Adam S	February 17, 2026	Buy	15,000	5.40	81,000
December 16, 2025	Director	Grossman Adam S	December 15, 2025	Sell	21,000	19.79	415,600
December 15, 2025	Director	Grossman Adam S	December 15, 2025	Buy	15,000	5.40	81,000
November 21, 2025	Director	Grossman Adam S	November 19, 2025	Buy	15,000	5.40	81,000
November 19, 2025	Director	Grossman Adam S	November 19, 2025	Sell	21,000	16.00	336,000
October 24, 2025	Director	Grossman Adam S	October 24, 2025	Buy	15,000	5.40	81,000
October 24, 2025	Director	Grossman Adam S	October 24, 2025	Sell	21,000	16.00	336,000
September 16, 2025	Director	Grossman Adam S	September 15, 2025	Buy	15,000	5.40	81,000
September 15, 2025	Director	Grossman Adam S	September 15, 2025	Sell	21,000	16.13	338,700

【Company Profile】

ADMA Biologics, Inc. was incorporated on June 24, 2004, in New Jersey. The company is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialized biologics for the treatment of immunodeficient patients at risk of infection and other individuals with specific infectious disease risks. The company’s target patient population includes individuals with potential immune deficiency diseases or those who may be immunosuppressed for medical reasons.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.